Shari N Gordon, Valentina Cecchinato, Vibeke Andresen, Jean-Michel Heraud, Anna Hryniewicz, Robyn Washington Parks, David Venzon, Hye-kyung Chung, Tatiana Karpova, James McNally, Peter Silvera, Keith A Reimann, Hajime Matsui, Tomomi Kanehara, Yasuhiko Shinmura, Hiroyuki Yokote, Genoveffa Franchini
The licensed smallpox vaccine, ACAM2000, is a cell culture derivative of Dryvax. Both ACAM2000 and Dryvax are administered by skin scarification and can cause progressive vaccinia, with skin lesions that disseminate to distal sites. We have investigated the immunologic basis of the containment of vaccinia in the skin with the goal to identify safer vaccines for smallpox. Macaques were depleted systemically of T or B cells and vaccinated with either Dryvax or an attenuated vaccinia vaccine, LC16m8. B cell depletion did not affect the size of skin lesions induced by either vaccine...
April 15, 2011: Journal of Infectious Diseases